COYA 302
Alternative Names: COYA-302Latest Information Update: 15 Mar 2024
At a glance
- Originator Coya Therapeutics
- Class Antidementias; Antiparkinsonians; Cytokines; Interleukins; Neuroprotectants; Recombinant fusion proteins
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis
- Preclinical Alzheimer's disease; Autoimmune disorders; Frontotemporal dementia; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 13 Mar 2024 Coya Therapeutics files for patent protection for relating to the use of the biomarker in ALS
- 13 Mar 2024 Interim pharmacodynamics data from a phase I trial in Amyotrophic lateral sclerosis released by Coya Therapeutics
- 12 Mar 2024 Preclinical trials in Alzheimer's disease in USA (SC) prior to March 2024